*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Oxytocin's social and stress-regulatory effects in children with autism and intellectual disability: a protocol for a randomized placebo-controlled trial BMC psychiatry · preclinical | PMID 40033311 |
| 2025 | Oxytocin and autism: Insights from clinical trials and animal models Current opinion in neurobiology · preclinical | PMID 40157057 |
| 2024 | Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications Peptides · preclinical | PMID 38579916 |
| 2024 | Acute, chronic and conditioned effects of intranasal oxytocin in the mu-opioid receptor knockout mouse model of autism: Social context matters Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · preclinical | PMID 39020142 |
| 2024 | Chronic oxytocin administration stimulates the oxytocinergic system in children with autism Nature communications · human | PMID 38167302 |
| 2024 | Oxytocin homogenizes horse group organization iScience · preclinical | PMID 39071893 |
| 2023 | The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial Molecular psychiatry · human | PMID 36302965 |
| 2023 | Intranasal Oxytocin and Pain Reduction: Testing a Social Cognitive Mediation Model Brain sciences · preclinical | PMID 38137136 |
| 2022 | Oxytocin-a social peptide? Deconstructing the evidence Philosophical transactions of the Royal Society of London. Series B, Biological sciences · preclinical | PMID 35858110 |
| 2021 | Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder The New England journal of medicine · human | PMID 34644471 |
| 2021 | Intranasal oxytocin drives coordinated social approach Scientific reports · preclinical | PMID 34504242 |
| 2021 | Intranasal oxytocin decreases self-oriented learning Psychopharmacology · human | PMID 33156402 |
| 2020 | An Allostatic Theory of Oxytocin Trends in cognitive sciences · preclinical | PMID 32360118 |
| 2018 | Oxytocin and Aggression Current topics in behavioral neurosciences · preclinical | PMID 28864975 |
| 2018 | Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis Psychoneuroendocrinology · preclinical | PMID 29032324 |
| 2018 | Oxytocin regulates social approach Social neuroscience · preclinical | PMID 29241395 |
| 2018 | Overview of Human Oxytocin Research Current topics in behavioral neurosciences · preclinical | PMID 28864976 |
| 2018 | Oxytocin and Animal Models for Autism Spectrum Disorder Current topics in behavioral neurosciences · preclinical | PMID 28864977 |
| 2017 | Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism Proceedings of the National Academy of Sciences of the United States of America · human | PMID 28696286 |
| 2016 | Intranasal Oxytocin: Myths and Delusions Biological psychiatry · preclinical | PMID 26049207 |
Oxytocin (Oxytocin). Nine-amino-acid hypothalamic/posterior-pituitary peptide hormone. Uterotonic and lactation roles peripherally; centrally modulates social bonding, trust, and stress.
Commonly discussed uses: labour induction / postpartum haemorrhage (approved, IV/IM), social-cognition and autism research (intranasal, investigational). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Nine-amino-acid hypothalamic/posterior-pituitary peptide hormone. Uterotonic and lactation roles peripherally; centrally modulates social bonding, trust, and stress.
Reported considerations: obstetric: uterine hyperstimulation, hyponatraemia with high-dose/fluid load, intranasal research: generally mild. There is both human and animal/preclinical research, though the depth and quality vary by indication. Approved prescription medicine for obstetric indications. Intranasal behavioural use is investigational/off-label. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low obstetric: titrated IV, typical research intranasal 24 IU, high protocol-defined. Administration: intravenous, intramuscular, intranasal (research). Half-life: ~3-5 minutes.
Australian status: Prescription-only; registered for obstetric use. Approved prescription medicine for obstetric indications. Intranasal behavioural use is investigational/off-label. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: per registered product (injectable solution); storage: refrigerated per label.
Commonly discussed combinations (anecdotal for unapproved compounds): clinical obstetric use directed by clinician. Stacking increases interaction/safety uncertainty.